MICRORNAS DIFFERENTIALLY EXPRESSED IN LUNG DISEASES AND USES THEREOF

• US 20090186015A1
• Filed: 10/17/2008
• Published: 07/23/2009
• Est. Priority Date: 10/18/2007
• Status: Abandoned Application

• Current Assignee: Asuragen, Inc. (Bio-Techne Corporation)
• Original Assignee: Asuragen, Inc. (Bio-Techne Corporation)
• Inventors: Latham, Gary J., Peltier, Heidi J.
• Application Number:
  US12/253,718
• Publication Number:
  US 20090186015A1
• Time in Patent Office: Days
• US Class Current: 424/130.100
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/178 miRNA, siRNA or ncRNA

Abstract

The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as lung cancer, and using the profile in assessing the condition of a patient.

Claims

1. A method for diagnosing lung cancer in a patient comprising evaluating expression of miR-221 and/or miR-195 in one or more samples from the patient, wherein a difference in the expression in the sample from the patient and expression in a normal sample or reference is indicative of lung cancer.

2. The method of claim 1, further comprising evaluating expression of miR-93.

3. The method of claim 1, wherein the miRNA is miR-221.

4. The method of claim 3, further comprising evaluating the expression of miR-93

5. The method of claim 4, further comprising evaluating the expression of miR-195.

6. The method of claim 1, wherein an increase in expression of miR-93, miR-221, or both miR-93 and miR-221 in a patient sample is indicative of lung cancer.

7. The method of claim 1, wherein a decrease in expression of miR-195 in a patient sample is indicative of lung cancer.

8. The method of claim 1, wherein the lung cancer is non-small cell lung cancer, small cell lung cancer, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, adenosquamous carcinoma, or undifferentiated carcinoma.

9. The method of claim 1, further comprising evaluating expression of one or more mRNA whose expression level is correlated with lung cancer.

10. The method of claim 9, wherein the mRNA measured is selected from the group comprising hnRNPB1, telomerase catalytic component (hTERT), EGFR, RAP1, survivin, osteopontin, CYFRA 21.1, and CEA.

12. The method of claim 1, wherein the sample is tissue, blood, serum, urine, sputum, or plasma sample.

13. The method of claim 12, wherein the sample is fresh, frozen, fixed, or embedded.

14. The method of claim 1, wherein the sample from the patient and the normal sample are lung samples.

15. The method of claim 1, further comprising obtaining a sample from the patient.

17. The method of claim 1, wherein expression of the miRNA is determined by an amplification assay or a hybridization assay.

19. The method of claim 17, wherein the quantitative amplification assay is quantitative RT-PCR.

21. The method of claim 1, wherein diagnosing is screening for a pathological condition, assessing prognosis of a pathological condition, staging a pathological condition, or assessing response of a pathological condition to therapy.

22. The method of claim 1, further comprising providing a report of the evaluation.

11. (canceled)

16. (canceled)

18. (canceled)

20. (canceled)

23. A method of treating a patient comprising obtaining a measure of expression for miR-221 and/or miR-195 and selecting treatment based on the measure of miR-221 or miR-195 expression.

24-29. -29. (canceled)

30. A kit for analysis of a sample by assessing miRNA profile for a sample comprising, in suitable container means, two or more miRNA hybridization or amplification reagents comprising one or more probe or amplification primer for miR-221, miR-93, or miR-195.

31-33. -33. (canceled)